Washington, D.C. (September 30, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) associate general counsel, John Murphy, issued the following statement regarding the Centers for Medicare & Medicaid Services’ (CMS) public release of the Open Payments database – a database established through the Physician Payments Sunshine Act included in the Affordable Care Act.
“PhRMA supports the Sunshine Act and is committed to its successful implementation. Collaborations between biopharmaceutical manufacturers and physicians, including clinician researchers and physician scientists, play an important role in advancing innovation and science. For this reason, the industry has voluntarily worked to improve transparency regarding physician collaborations by reporting data and complying with professional codes of conduct.
While we are currently reviewing the data released by CMS, we are hopeful it includes sufficient context, so patients have a clear understanding regarding the important physician and manufacturer collaborations that occur and to help patients make accurate and informed health care decisions. We hope to work with CMS to refine the data collection process and content structure for the next iteration of the Open Payments database.”
Sunshine Act and Open Payments Database Letters
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.
Find PhRMA Online
Website – http://www.phrma.org
Facebook – www.facebook.com/PhRMA
Blog – www.phrma.org/catalyst
YouTube – www.youtube.com/PhRMApress